Galapagos subsidiary Argenta has signed an agreement with Boehringer Ingelheim to provide respiratory drug discovery services for “an undisclosed target within Boehringer Ingelheim’s respiratory disease portfolio,” the company said. On its website, Argenta says that it generally expects nomination of a respiratory drug candidate within 2 years and has nominated 16 respiratory drug candidates, both oral and inhaled, within the past 5 years.
Argenta Managing Director John Montana commented, “We are delighted to have secured this contract with Boehringer Ingelheim, one of the world’s leading companies in the development of drugs for respiratory diseases, and it is testament to the strength and depth of Argenta’s integrated drug discovery capabilities and expertise in this therapeutic area. We look forward to a fruitful collaboration leading to the delivery of pre-clinical candidates against the target of interest.”
Read the Argenta press release.
